Abstract: The invention relates to an assay for discriminating between amyotrophic lateral sclerosis (ALS) patients and patients with ALS-like disorders that express symptoms like ALS. The method is based on the use of 2-dimensional (2D) gel electrophoresis to separate the complex mixture of proteins found in blood serum, the quantitation of a group of identified biomarkers, and the biostatistical analysis of the concentration of the identified biomarkers to differentiate patients having ALS from patients having other ALS-like disorders.

Abstract: The invention relates to 12 identified protein biomarkers for diagnosis, determination of disease severity, and therapeutic response monitoring of patients with breast cancer. The method is based on the use of 2-dimensional (2D) gel electrophoresis to separate the complex mixture of proteins found in blood serum, the quantitation of up to 12 protein biomarkers, and statistical analysis of the concentration of the protein biomarkers.

Abstract: The invention relates to assays for diagnosis, drug targeting and therapeutic response monitoring, of patients with Parkinson's disease (PD), with PD-Like disorders that express symptoms like PD, age-matched controls (Normal), Patients with Amyotrophic Lateral Sclerosis (ALS), with ALS-Like disorders that express symptoms like ALS, and age-matched controls (Normal). The method is based on the use of 2-dimensional (2D) gel electrophoresis to separate the complex mixture of proteins found in blood serum, the quantitation of a group of identified biomarkers, and the biostatistical analysis of the concentration of the identified biomarkers.

Abstract: The invention relates to 5 identified protein biomarkers, gamma- and beta-Actin proteins, for screening, diagnosis, drug targeting, and drug design for resistance of cancer to an Ab1 kinase inhibitor. The method is based on the use of two-dimensional (2D) gel electrophoresis to separate the complex mixture of proteins found in bone marrow aspirate samples, taken from patients at time of diagnosis of Chronic Myelogenous Leukemia (CML), the quantitation of 5 protein spots identified as beta- and/or gamma-Actin proteins, to differentiate between patients who will respond to or resist treatment when the patients are subsequently treated with an Ab1 kinase inhibitor.